Calyxt Files $50M IPO

Calyxt, a spin-off of Cellectis (NASDAQ: CLLS), files a $50 million IPO on form S-1 with the SEC.

The offering is being led by Citigroup, Credit Suisse and Jefferies.

Calyxt is a consumer-centric, food- and agriculture-focused company. By combining leading gene-editing technology and technical expertise with our innovative commercial strategy, they are pioneering a paradigm shift to deliver healthier specialty food ingredients, such as healthier oils and high fiber wheat, for consumers and agriculturally advantageous crop traits, such as herbicide tolerance, to farmers.

You May Also Be Interested In